<?xml version='1.0' encoding='utf-8'?>
<document id="30754071"><sentence text="The effect of naringenin on the pharmacokinetics of ibrutinib in rat: A drug-drug interaction study."><entity charOffset="14-24" id="DDI-PubMed.30754071.s1.e0" text="naringenin" /><entity charOffset="52-61" id="DDI-PubMed.30754071.s1.e1" text="ibrutinib" /><pair ddi="false" e1="DDI-PubMed.30754071.s1.e0" e2="DDI-PubMed.30754071.s1.e0" /><pair ddi="false" e1="DDI-PubMed.30754071.s1.e0" e2="DDI-PubMed.30754071.s1.e1" /></sentence><sentence text="The aim of this study was to investigate the effect of naringenin on the pharmacokinetics of ibrutinib in rats"><entity charOffset="55-65" id="DDI-PubMed.30754071.s2.e0" text="naringenin" /><entity charOffset="93-102" id="DDI-PubMed.30754071.s2.e1" text="ibrutinib" /><pair ddi="false" e1="DDI-PubMed.30754071.s2.e0" e2="DDI-PubMed.30754071.s2.e0" /><pair ddi="false" e1="DDI-PubMed.30754071.s2.e0" e2="DDI-PubMed.30754071.s2.e1" /></sentence><sentence text=" A simple and sensitive quantitation method based on ultra-high-performance liquid chromatography-Q-Exactive Orbitrap tandem mass spectrometry was developed and validated for the determination of ibrutinib in rat plasma"><entity charOffset="196-205" id="DDI-PubMed.30754071.s3.e0" text="ibrutinib" /></sentence><sentence text=" The samples were extracted using ethyl acetate containing 1% triethylamine and separated on a Waters Acquity UPLC BEH C18 column with acetonitrile and water containing 0"><entity charOffset="34-47" id="DDI-PubMed.30754071.s4.e0" text="ethyl acetate" /><entity charOffset="62-75" id="DDI-PubMed.30754071.s4.e1" text="triethylamine" /><entity charOffset="135-147" id="DDI-PubMed.30754071.s4.e2" text="acetonitrile" /><pair ddi="false" e1="DDI-PubMed.30754071.s4.e0" e2="DDI-PubMed.30754071.s4.e0" /><pair ddi="false" e1="DDI-PubMed.30754071.s4.e0" e2="DDI-PubMed.30754071.s4.e1" /><pair ddi="false" e1="DDI-PubMed.30754071.s4.e0" e2="DDI-PubMed.30754071.s4.e2" /><pair ddi="false" e1="DDI-PubMed.30754071.s4.e1" e2="DDI-PubMed.30754071.s4.e1" /><pair ddi="false" e1="DDI-PubMed.30754071.s4.e1" e2="DDI-PubMed.30754071.s4.e2" /></sentence><sentence text="1% formic acid as mobile phase"><entity charOffset="3-14" id="DDI-PubMed.30754071.s5.e0" text="formic acid" /></sentence><sentence text=" The assay showed good linearity over the concentration range of 1-1000 ng/mL with coefficient of correlation &gt;0" /><sentence text="995" /><sentence text=" The LLOQ was 1 ng/mL" /><sentence text=" The assay showed acceptable precision (RSD &lt; 8" /><sentence text="65%), accuracy (RE within ±15%), extraction recovery (&gt;78" /><sentence text="25%) and negligible matrix effects" /><sentence text=" The validated method has been successfully applied to the pharmacokinetic study of ibrutinib in rats after oral administration of ibrutinib with or without coadministration of naringenin"><entity charOffset="84-93" id="DDI-PubMed.30754071.s12.e0" text="ibrutinib" /><entity charOffset="131-140" id="DDI-PubMed.30754071.s12.e1" text="ibrutinib" /><entity charOffset="177-187" id="DDI-PubMed.30754071.s12.e2" text="naringenin" /><pair ddi="false" e1="DDI-PubMed.30754071.s12.e0" e2="DDI-PubMed.30754071.s12.e0" /><pair ddi="false" e1="DDI-PubMed.30754071.s12.e0" e2="DDI-PubMed.30754071.s12.e1" /><pair ddi="false" e1="DDI-PubMed.30754071.s12.e0" e2="DDI-PubMed.30754071.s12.e2" /><pair ddi="false" e1="DDI-PubMed.30754071.s12.e1" e2="DDI-PubMed.30754071.s12.e1" /><pair ddi="false" e1="DDI-PubMed.30754071.s12.e1" e2="DDI-PubMed.30754071.s12.e2" /></sentence><sentence text=" Our results demonstrated that naringenin could significantly affect the pharmacokinetics of ibrutinib, including prolonging its half-life, increase the area under the concentration-time curve and reducing its clearance time"><entity charOffset="31-41" id="DDI-PubMed.30754071.s13.e0" text="naringenin" /><entity charOffset="93-102" id="DDI-PubMed.30754071.s13.e1" text="ibrutinib" /><pair ddi="false" e1="DDI-PubMed.30754071.s13.e0" e2="DDI-PubMed.30754071.s13.e0" /><pair ddi="false" e1="DDI-PubMed.30754071.s13.e0" e2="DDI-PubMed.30754071.s13.e1" /></sentence><sentence text=" This study indicated that there is potential for drug-drug interactions between naringenin and ibrutinib, and coadministration of ibrutinib with naringenin or naringenin-containing herbal medicines should be avoided in the clinic"><entity charOffset="81-91" id="DDI-PubMed.30754071.s14.e0" text="naringenin" /><entity charOffset="96-105" id="DDI-PubMed.30754071.s14.e1" text="ibrutinib" /><entity charOffset="131-140" id="DDI-PubMed.30754071.s14.e2" text="ibrutinib" /><entity charOffset="146-156" id="DDI-PubMed.30754071.s14.e3" text="naringenin" /><entity charOffset="160-170" id="DDI-PubMed.30754071.s14.e4" text="naringenin" /><pair ddi="false" e1="DDI-PubMed.30754071.s14.e0" e2="DDI-PubMed.30754071.s14.e0" /><pair ddi="false" e1="DDI-PubMed.30754071.s14.e0" e2="DDI-PubMed.30754071.s14.e1" /><pair ddi="false" e1="DDI-PubMed.30754071.s14.e0" e2="DDI-PubMed.30754071.s14.e2" /><pair ddi="false" e1="DDI-PubMed.30754071.s14.e0" e2="DDI-PubMed.30754071.s14.e3" /><pair ddi="false" e1="DDI-PubMed.30754071.s14.e0" e2="DDI-PubMed.30754071.s14.e4" /><pair ddi="false" e1="DDI-PubMed.30754071.s14.e1" e2="DDI-PubMed.30754071.s14.e1" /><pair ddi="false" e1="DDI-PubMed.30754071.s14.e1" e2="DDI-PubMed.30754071.s14.e2" /><pair ddi="false" e1="DDI-PubMed.30754071.s14.e1" e2="DDI-PubMed.30754071.s14.e3" /><pair ddi="false" e1="DDI-PubMed.30754071.s14.e1" e2="DDI-PubMed.30754071.s14.e4" /><pair ddi="false" e1="DDI-PubMed.30754071.s14.e2" e2="DDI-PubMed.30754071.s14.e2" /><pair ddi="false" e1="DDI-PubMed.30754071.s14.e2" e2="DDI-PubMed.30754071.s14.e3" /><pair ddi="false" e1="DDI-PubMed.30754071.s14.e2" e2="DDI-PubMed.30754071.s14.e4" /><pair ddi="false" e1="DDI-PubMed.30754071.s14.e3" e2="DDI-PubMed.30754071.s14.e3" /><pair ddi="false" e1="DDI-PubMed.30754071.s14.e3" e2="DDI-PubMed.30754071.s14.e4" /></sentence><sentence text="" /></document>